Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus Nephritis
Obrișcă et al.,
Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus Nephritis,
Biomedicines, doi:10.3390/biomedicines10102423
Prospective analysis of 95 Lupus Nephritis patients in Romania, showing lower risk of COVID-19 with HCQ use.
risk of case, 86.7% lower, RR 0.13, p = 0.01, treatment 10 of 81 (12.3%), control 5 of 14 (35.7%), NNT 4.3, adjusted per study, odds ratio converted to relative risk, multivariable.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Obrișcă et al., 28 Sep 2022, prospective, Romania, peer-reviewed, mean age 39.0, 12 authors, study period 26 February, 2020 - 1 May, 2021.
Contact:
bogdan.obrisca@drd.umfcd.ro (corresponding author).
Abstract: biomedicines
Article
Characteristics of SARS-CoV-2 Infection in an Actively
Monitored Cohort of Patients with Lupus Nephritis
Bogdan Obris, că 1,2, *,† , Alexandra Vornicu 1,2,† , Roxana Jurubit, ă 1 , Valentin Mocanu 1 , George Dimofte 1 ,
Andreea Andronesi 1,2 , Bogdan Sorohan 1,2 , Camelia Achim 1,2 , Georgia Micu 1 , Raluca Bobeică 1 ,
Constantin Dina 3,† and Gener Ismail 1,2,†
1
2
3
*
†
Citation: Obris, că, B.; Vornicu, A.;
Jurubit, ă, R.; Mocanu, V.; Dimofte, G.;
Andronesi, A.; Sorohan, B.; Achim,
C.; Micu, G.; Bobeică, R.; et al.
Characteristics of SARS-CoV-2
Infection in an Actively Monitored
Cohort of Patients with Lupus
Nephritis. Biomedicines 2022, 10, 2423.
https://doi.org/10.3390/
biomedicines10102423
Academic Editor: Cristina Capusa
Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania
Department of Nephrology, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
Department of Anatomy, Ovidius University, 900470 Constant, a, Romania
Correspondence: bogdan.obrisca@drd.umfcd.ro
These authors contributed equally to this work.
Abstract: (1) Background: We sought to investigate the impact of the COVID-19 pandemic in patients
with lupus nephritis (LN); (2) Methods: A total of 95 patients with LN actively monitored in our
department between 26 February 2020, when the first case of COVID-19 was diagnosed in Romania,
and 1 May 2021, were included in the study. Multivariate logistic regression analysis was performed
to identify the independent risk factors for SARS-CoV-2 infection; (3) Results: A total of 15 patients
(15.8%) had a confirmed SARS-CoV-2 infection during a total follow-up time of 105.9 patient-years
(unadjusted incidence rate: 14.28 SARS-CoV-2 infections per 100 patient-years). Median time to
SARS-CoV-2 infection was 9.3 months (IQR: 7.2–11.3). The majority of patients had a mild form
of SARS-CoV-2 infection (73.3%), while the remaining had moderate forms. None of the patients
had a severe infection or a SARS-CoV-2-related death. The most frequent symptom was fatigue
(73.3%), followed by loss of taste/smell (53.3%) and fever (46.7%). Forty percent of those with SARSCoV-2 infection were hospitalized for a median 11.5 days (IQR:3.75–14). In the multivariate logistic
regression analysis, a current oral corticosteroid dose ≥ 15 mg/day was associated with a 7.69-fold
higher risk (OR, 7.69; 95%, 1.3–45.46), while the use of hydroxychloroquine was associated with a
91% lower risk for a SARS-CoV-2 infection (OR, 0.09; 95%CI, 0.01–0.59). (4) Conclusions: Our study
confirms that the SARS-CoV-2 infection-associated morbidity might only be moderately increased in
patients with LN. The current oral corticosteroid dose was the only independent predictor of infection
occurrence, while use of hydroxychloroquine was associated with a protective effect.
Keywords: lupus nephritis; SARS-CoV-2 infection; corticosteroids; hydroxychloroquine
Received: 27 August 2022
Accepted: 24 September 2022
Published: 28 September 2022
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.
Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit